Skip to main content

Context Therapeutics Inc.

For the period ended Dec 31, 2024. Filed Mar 20, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 20, 2025

CNTX$0.20+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CONTEXT THERAPEUTICS INC.
By:/s/ Martin Lehr
Martin Lehr
March 20, 2025Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SIGNATURETITLEDATE
/s/ Martin LehrChief Executive Officer and Director (Principal Executive Officer)March 20, 2025
Martin Lehr
/s/ Jennifer Minai-AzaryChief Financial Officer(Principal Financial and Accounting Officer)March 20, 2025
Jennifer Minai-Azary
/s/ Andy PasternakChairman of the Board and DirectorMarch 20, 2025
Andy Pasternak
/s/ Philip KantoffDirectorMarch 20, 2025
Philip Kantoff
/s/ Karen SmithDirectorMarch 20, 2025
Karen Smith
/s/ Jennifer Evans StaceyDirectorMarch 20, 2025
Jennifer Evans Stacey
/s/ Luke WalkerDirectorMarch 20, 2025
Luke Walker
/s/ Linda WestDirectorMarch 20, 2025
Linda West
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.